SEC Form 4 · accession 0001190725-17-000148
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Reisman
Director
Period of report
Jun 22, 2017
Accepted (ET)
Jun 26, 2017 · 8:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $4.05 | Jun 22, 2017 | A | 25,000 | A | — | Jun 21, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant.